CP1: Began Phase II testing

Nortran Pharmaceuticals Inc. (CDNX:NRT; NTRDF), Vancouver, B.C. Product: CP1 Business: Neurological Therapeutic category: Neurotransmission Target: Peripheral nerve endings in the airway Description: ...